Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (SINTRA-REV)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Fundación General de la Universidad de Salamanca
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Fundación General de la Universidad de Salamanca
ClinicalTrials.gov Identifier:
NCT01243476
First received: November 17, 2010
Last updated: July 21, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2020
  Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)